- SCP22: Australian response to GRULAC proposal to revise 1979 WIPO Model Law for Developing Countries on Inventions
- WIPO SCP22: KEI statement on GRULAC proposal (SCP/22/5)
- SCP22: India’s Intervention on inventive step (SCP/22/3)
- SCP22: Opening statement of the Group of Latin American and Caribbean Countries
- USTR proposals in TPP are in conflict with U.S. Supreme Court decisions on State Sovereign Immunity
- Eleven of the 28 House democrats supporting Fast Track write USTR about Medicine IPR issues
- WIPO Standing Committee on the Law of Patents: What's on the agenda?
- Sanders offers amendment to create compulsory licenses on medical inventions, for veterans
- KEI letter to Register of Copyrights, USPTO and OSTP on copyright issues in TPP
- Mylan criticisms of the TPP provisions as regards generic medicines, warns USTR on "lazy drafting"
SCP22: Australian response to GRULAC proposal to revise 1979 WIPO Model Law for Developing Countries on InventionsSubmitted by thiru on 29. July 2015 - 9:59
On 29 July 2015, Australia provided the following response to the proposal by the Group of Latin American and Caribbean Countries (GRULAC) to revise the 1979 WIPO Model Law for Developing Countries on Inventions.
Australian Delegation Proposal
The Secretariat prepare a study on:
1) experiences of how developing countries and least developed countries (LDCs) have implemented the patent model law; or
2) to determine the unmet need for a patent model law.
Knowledge Ecology International (KEI) delivered the following intervention on 29 July 2015 during WIPO discussions on the proposal by the Group of Latin American and Caribbean Countries (GRULAC) to revise the 1979 WIPO Model Law for Developing Countries on Inventions.
KEI statement on GRULAC proposal (SCP/22/5)
WIPO Standing Committee on the Law of Patents (SCP)
29 July 2015
Proposal: Engage Member States in the Revision of the 1979 WIPO Model Law for Developing Countries on Inventions
India delivered this lengthy, nuanced intervention on inventive step on 28 July 2015 citing the US Supreme Court observations on a person skilled in the art (PSIA), the KSR Int'l Co. v. Teleflex, Inc. decision on obviousness as applied to patent claims, the IPAB Roche decision (in relation to inventive step) and jurisprudence from the House of Lords on inventive step.
India’s Intervention on a study on inventive step (SCP/22/3) at SCP/22
On Monday afternoon, 27 July 2015, Brazil on behalf of the Group of Latin American and Caribbean Countries (GRULAC) delivered the following opening statement which,inter alia, called for a
Attached is a letter from eleven of the 28 House Democrats that supported the Trade Promotion Authority (TPA) Fast Track legislation, on the topic of intellectual property rights and medicine. The letter, which is moderate and cautious in substance, but overall helpful given where negotiations stand, closes by telling Ambassador Froman that "As members who support trade done right, we strongly believe that TPP must not inhibit access to lifesaving medicines."
The World Intellectual Property Organization's (WIPO) Twenty-Second session of the Standing Committee on the Law of Patents (SCP) is taking place from 27 July 2015 to 31 July 2015 in Geneva, Switzerland. The prior session of the Committee (November 2014) ended in deadlock. Ultimately, patents and health proved to be the deciding factor.
On Wednesday, July 22, 2015, the Senate Veterans Committee held a mark-up to consider several bills. During the mark-up, Senator Sanders offered an amendment, attached below, that would create a compulsory license mechanism in the Department of Veterans Affairs, for patents on medical inventions. (See amendment text below). The motivation for the amendment was a crisis in the VA involving access to drugs for the hepatitis C virus (HCV).
On the topic of the TPP and copyright, KEI has sent a letter to Maria Pallante, the Register of Copyrights, Shira Perlmutter, Chief Policy Officer and Director for International Affairs for USPTO, and Nancy Weiss, Senior Advisor to the Chief Technology Officer, Office of Science and Technology Policy (OSTP), Executive Office of the President.
KEI asked these agencies to address certain issues in the TPP intellectual property chapter that relate to access to copyright issues, with a focus on orphan works, and uses by governments.
On Thursday, 23 July 2015, at 11AM Eastern Time (Washington, DC), KEI will host a seminar on drug pricing featuring Dr. Ruth Lopert, the Deputy Director of Pharmaceutical Policy and Strategy at the Center for Pharmaceutical Management, at Management Sciences for Health (MSH).
EU Trade Commissioner Backs LDC Request for TRIPS Exemption for Pharmaceuticals Until Graduation from LDC StatusSubmitted by thiru on 16. July 2015 - 9:35
In a comprehensive, 2000 word speech to the European Parliament's International Trade Committee (INTA) on Modernising Trade Policy - Effectiveness and Responsibility, European Trade Commissioner, Cecilia Malmström, cast a wide net in her speech covering in her words, 1) the "benefits of trade for all: our economy in general, consumers, entrepreneurs, SMEs and the poorest countries", 2) "trade policy's commitment to our values in the world, supporting our foreign policy, promoting the respect of human rights, soci
On 20 March 2015, the European Union published a position paper on intellectual property outlining its priorities for the Transatlantic Trade and Investment Partnership (TTIP). At the time of publication of this position paper, the EU noted that "the U.S. has not yet formally identified the areas of interest that it could consider as priorities."
10th TTIP Stakeholder Event, Round 10
SESSION 2 Issues related to intellectual property including Geographical Indications and public health
15 July 2015
Knowledge Ecology International
A Positive Agenda for TTIP
My presentation today will address creating a positive agenda for TTIP focusing on the following six themes
1. Cooperation in funding R&D as a public good
2. Promoting the transparency of drug development costs, revenues, and prices
3. Standards for putting government funded research data and articles into free public archives
Attached below is a letter KEI sent to Emily Bleimund, Senior Policy Advisor for International Trade for the Department of Health and Human Services (HHS), and several other U.S. trade officials. The letter addresses three issues in the TPP text:
- There is a need for exceptions to exclusive rights in pharmaceutical and biologic drug test data.
- WTO standards for compulsory licenses should not be modified as part of a secret negotiation, or constrained by a 3-step test.